Literature DB >> 20617791

Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.

Takashi Yamamoto1, Padma Nair, Neil E Jacobsen, Vinod Kulkarni, Peg Davis, Shou-Wu Ma, Edita Navratilova, Henry I Yamamura, Todd W Vanderah, Frank Porreca, Josephine Lai, Victor J Hruby.   

Abstract

Neuropathic pain states and tolerance to opioids can result from system changes in the CNS, such as up-regulation of the NK1 receptor and substance P, lead to antiopioid effects in ascending or descending pain-signaling pathways. Bifunctional compounds, possessing both the NK1 antagonist pharmacophore and the opioid agonist pharmacophore with delta-selectivity, could counteract these system changes to have significant analgesic efficacy without undesirable side effects. As a result of the introduction of cyclic and topological constraints with penicillamines, 2 (Tyr-cyclo[d-Pen-Gly-Phe-Pen]-Pro-Leu-Trp-NH-[3',5'-(CF(3))(2)-Bzl]) was found as the best bifunctional compound with effective NK1 antagonist and potent opioid agonist activities, and 1400-fold delta-selectivity over the mu-receptor. The NMR structural analysis of 2 revealed that the relative positioning of the two connected pharmacophores as well as its cyclic and topological constraints might be responsible for its excellent bifunctional activities as well as its significant delta-opioid selectivity. Together with the observed high metabolic stability, 2 could be considered as a valuable research tool and possibly a promising candidate for a novel analgesic drug.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20617791      PMCID: PMC2943425          DOI: 10.1021/jm100157m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  46 in total

1.  Structure of outer membrane protein A transmembrane domain by NMR spectroscopy.

Authors:  A Arora; F Abildgaard; J H Bushweller; L K Tamm
Journal:  Nat Struct Biol       Date:  2001-04

Review 2.  Designed multiple ligands. An emerging drug discovery paradigm.

Authors:  Richard Morphy; Zoran Rankovic
Journal:  J Med Chem       Date:  2005-10-20       Impact factor: 7.446

Review 3.  An evaluation of computational strategies for use in the determination of protein structure from distance constraints obtained by nuclear magnetic resonance.

Authors:  T F Havel
Journal:  Prog Biophys Mol Biol       Date:  1991       Impact factor: 3.667

4.  [L-Ala3]DPDPE: a new enkephalin analog with a unique opioid receptor activity profile. Further evidence of delta-opioid receptor multiplicity.

Authors:  R C Haaseth; P J Horan; E J Bilsky; P Davis; T Zalewska; J Slaninova; H I Yamamura; S J Weber; T P Davis; F Porreca
Journal:  J Med Chem       Date:  1994-05-27       Impact factor: 7.446

5.  Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance.

Authors:  K Wüthrich; M Billeter; W Braun
Journal:  J Mol Biol       Date:  1983-10-05       Impact factor: 5.469

6.  A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton-proton cross-relaxation networks in biological macromolecules.

Authors:  A Kumar; R R Ernst; K Wüthrich
Journal:  Biochem Biophys Res Commun       Date:  1980-07-16       Impact factor: 3.575

7.  The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Neil E Jacobsen; Peg Davis; Shou-wu Ma; Edita Navratilova; Sharif Moye; Josephine Lai; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2008-09-27       Impact factor: 7.446

8.  The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety.

Authors:  Takashi Yamamoto; Padma Nair; Shou-wu Ma; Peg Davis; Henry I Yamamura; Todd W Vanderah; Frank Porreca; Josephine Lai; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2009-08-21       Impact factor: 3.641

9.  Opioid regulation of mucosal ion transport in the mouse isolated jejunum.

Authors:  R J Sheldon; P J Rivière; M E Malarchik; H I Moseberg; T F Burks; F Porreca
Journal:  J Pharmacol Exp Ther       Date:  1990-04       Impact factor: 4.030

10.  Structure-activity relationships of novel cyclic alpha-MSH/beta-MSH hybrid analogues that lead to potent and selective ligands for the human MC3R and human MC5R.

Authors:  Preeti Balse-Srinivasan; Paolo Grieco; Minying Cai; Dev Trivedi; Victor J Hruby
Journal:  J Med Chem       Date:  2003-08-14       Impact factor: 7.446

View more
  7 in total

1.  Neurokinin 1 and opioid receptors: relationships and interactions in nervous system.

Authors:  Jie Xiao; Si Zeng; Xiangrui Wang; Hasan Babazada; Zhanchun Li; Renyu Liu; Weifeng Yu
Journal:  Transl Perioper Pain Med       Date:  2016

2.  Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist.

Authors:  Steven Ballet; Debby Feytens; Koen Buysse; Nga N Chung; Carole Lemieux; Suneeta Tumati; Attila Keresztes; Joost Van Duppen; Josephine Lai; Eva Varga; Frank Porreca; Peter W Schiller; Jozef Vanden Broeck; Dirk Tourwé
Journal:  J Med Chem       Date:  2011-03-17       Impact factor: 7.446

3.  Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics.

Authors:  Cecilia Betti; Joanna Starnowska; Joanna Mika; Jolanta Dyniewicz; Lukasz Frankiewicz; Alexandre Novoa; Marta Bochynska; Attila Keresztes; Piotr Kosson; Wioletta Makuch; Joost Van Duppen; Nga N Chung; Jozef Vanden Broeck; Andrzej W Lipkowski; Peter W Schiller; Frans Janssens; Marc Ceusters; François Sommen; Theo Meert; Barbara Przewlocka; Dirk Tourwé; Steven Ballet
Journal:  ACS Med Chem Lett       Date:  2015-10-31       Impact factor: 4.345

4.  Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist - neurokinin-1 antagonist peptidomimetics.

Authors:  Karel Guillemyn; Patrycia Kleczkowska; Anna Lesniak; Jolanta Dyniewicz; Olivier Van der Poorten; Isabelle Van den Eynde; Attila Keresztes; Eva Varga; Josephine Lai; Frank Porreca; Nga N Chung; Carole Lemieux; Joanna Mika; Ewelina Rojewska; Wioletta Makuch; Joost Van Duppen; Barbara Przewlocka; Jozef Vanden Broeck; Andrzej W Lipkowski; Peter W Schiller; Dirk Tourwé; Steven Ballet
Journal:  Eur J Med Chem       Date:  2014-12-19       Impact factor: 6.514

5.  Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Authors:  Padma Nair; Takashi Yamamoto; Scott Cowell; Vinod Kulkarni; Sharif Moye; Edita Navratilova; Peg Davis; Shou-Wu Ma; Todd W Vanderah; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2015-06-15       Impact factor: 2.823

6.  Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Authors:  Padma Nair; Takashi Yamamoto; Tally M Largent-Milnes; Scott Cowell; Vinod Kulkarni; Sharif Moye; Edita Navratilova; Peg Davis; Shou-Wu Ma; Todd W Vanderah; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2013-07-02       Impact factor: 2.823

7.  In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera.

Authors:  Karel Guillemyn; Patrycja Kleczkowska; Alexandre Novoa; Bart Vandormael; Isabelle Van den Eynde; Piotr Kosson; Muhammad Faheem Asim; Peter W Schiller; Mariana Spetea; Andrzej W Lipkowski; Dirk Tourwé; Steven Ballet
Journal:  Mol Brain       Date:  2012-01-30       Impact factor: 4.041

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.